StreetInsider.com News Articles

Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: Point72 Asset Management, L.P.

Tue, 17 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260217/26014066.html

Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: Point72 Asset Management, L.P.

Tue, 17 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260217/26014066.html

Form 5 Kodiak Sciences Inc. For: Dec 31 Filed by: PERLROTH VICTOR

Tue, 17 Feb 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26012830.html

Form 5 Kodiak Sciences Inc. For: Dec 31 Filed by: PERLROTH VICTOR

Tue, 17 Feb 2026 16:12:00 -0500

si-local-file:///var/storage/secattach/20260217/26012830.html

Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: PERLROTH VICTOR

Tue, 17 Feb 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260217/26012635.html

Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: PERLROTH VICTOR

Tue, 17 Feb 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260217/26012635.html

H.C. Wainwright Reiterates Buy Rating on Kodiak Sciences Inc. (KOD)

Tue, 10 Feb 2026 06:53:25 -0500

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $38.00 price target on Kodiak Sciences Inc. (NASDAQ: KOD).

The analyst commented: "We highlight final Phase 1B APEX trial results that were presented for anti-VEGF and anti-IL-6 bispecific KSI-101 in the treatment of macular edema secondary to inflammation (MESI) patients, at the Angiogenesis 2026 meeting. This first-time end-of-study dataset included Week 24 data that we believe positively supports the anatomical and visual improvements in MESI patients observed from earlier timepoints. With the current Phase 3 PEAK and PINNACLE trials enrolling for MESI patients (5mg and 10mg dosing), we here discuss our

Kodiak Sciences to present final KSI-101 phase 1b study results

Wed, 04 Feb 2026 07:01:25 -0500

Kodiak Sciences Inc. (NASDAQ: KOD) will present final results from its Phase 1b APEX study of KSI-101 for macular edema secondary to inflammation at the Angiogenesis annual meeting on February 7, 2026.

Dr. Sumit Sharma from the Cole Eye Institute will present the end-of-study clinical results, including Week 24 data, at 5:15 PM EST. The presentation marks the first time complete results from the APEX study will be disclosed publicly.

KSI-101 is a bispecific protein targeting IL-6 and VEGF at 100 mg/mL concentration. The APEX study evaluated the drug in two patient groups: those with diabetic macular edema and those with macular

Kodiak Sciences to present final KSI-101 phase 1b study results

Wed, 04 Feb 2026 07:01:25 -0500

KSI-101 is a bispecific protein targeting IL-6 and VEGF at 100 mg/mL concentration. The APEX study evaluated the drug in two patient groups: those with diabetic macular edema and those with macular

Kodiak Sciences to present final KSI-101 phase 1b study results

Wed, 04 Feb 2026 07:01:25 -0500

KSI-101 is a bispecific protein targeting IL-6 and VEGF at 100 mg/mL concentration. The APEX study evaluated the drug in two patient groups: those with diabetic macular edema and those with macular

Kodiak Sciences to present final KSI-101 phase 1b study results

Wed, 04 Feb 2026 07:01:25 -0500

KSI-101 is a bispecific protein targeting IL-6 and VEGF at 100 mg/mL concentration. The APEX study evaluated the drug in two patient groups: those with diabetic macular edema and those with macular

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026